A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs ARC 520 (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Arrowhead Pharmaceuticals
- 11 Apr 2018 According to an Arrowhead Pharmaceuticals media release, clinical data will be presented at the International Liver Congress 2018 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL).
- 11 Apr 2018 Results presented in an Arrowhead Pharmaceuticals media release.
- 06 Dec 2017 According to an Arrowhead Pharmaceuticals media release, results from this trial were presented at the 22nd biennial HEP DART meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History